Nurix Therapeutics, Inc.
NRIX
$25.96
$0.080.31%
NASDAQ
| 05/31/2026 | 02/28/2026 | 11/30/2025 | 08/31/2025 | 05/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -2.71% | -11.45% | 9.49% | -98.83% | 22.87% |
| Total Depreciation and Amortization | 1.96% | -6.33% | -19.38% | -1.90% | 23.47% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 29.59% | 3.80% | -3.52% | -1.42% | 48.77% |
| Change in Net Operating Assets | -631.53% | 351.48% | -109.42% | 150.68% | -131.51% |
| Cash from Operations | -34.29% | -6.02% | -18.21% | 9.14% | -3.40% |
| Capital Expenditure | -85.26% | 79.63% | -89.27% | -1.35% | 23.24% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 177.32% | -2,341.76% | -89.70% | -28.30% | 155.61% |
| Cash from Investing | 175.10% | -35,887.86% | -99.31% | -29.40% | 180.03% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -99.67% | -91.54% | 20,333.59% | 19,150.00% | -99.59% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -99.67% | -91.54% | 20,333.59% | 19,150.00% | -99.59% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 98.00% | -204.30% | 3,028.27% | -168.97% | 124.48% |